It was my great pleasure to present Glycanostics® and our early-stage cancer diagnostic test Giasay® at the EIC & EuroQuity – Bpifrance Healthcare Investor Day on 23 October in Paris. It was a great […]
„Glycanostics® is going to be one of 25 most innovative companies that will compete at a pitch competition at the HealthTech Innovation Days (HTID®) in Paris. Please meet our CEO […]
Meet our CEO Eva Kovacova FCCA at the European Angel Investment Summit in Brussels on 10-11 October! Join me at the premier annual conference where angels, entrepreneurs, and change-makers come together to […]
The network of urologists who provide the Giasay® PROSTATE test is gradually expanding. Today, you can take the highly accurate prostate cancer test at specialist urology clinics in four regional […]
First Patent Certificate for EP Patent No. 3 775 909 for us! Availabe here.
New project: € 2.5 mil. funding signed for Novel serological glycan-based biomarkers for screening of breast, lung and pancreatic cancers
The Glycanostics cancer screening technology detects glycan changes (complex carbohydrates) attached to a protein in the blood. It is highly scalable due to the following unique characteristics: detects early-stage cancers […]
8th & 9th March, 2023, Brussels Our CEO Eva Kováčová is one of the organisers of the first summit by the EU Female Founders in Brussels under the sponsorship of […]
Glycanostics took another important step to improve its quality management system and has been granted with ISO 13485.
Glycanostics was selected as one of eight most innovative companies to participate in the MEDICAL FORGE Accelerator program 2023, which will facilitate and accelerate our entry to the German market. […]